Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Neubauer

Showing results (1-10 of 224) with videos related to

Pageof 23
Sort By:
Deutsches Arzteblatt International|January 24, 2015
Many questions left openAndreas Neubauer
Innere Medizin (Heidelberg, Germany)|February 22, 2024
[Precision medicine]Andreas Neubauer
Neural Networks : the Official Journal of the International Neural Network Society|February 11, 2003
Analysis of Tikhonov regularization for function approximation by neural networksMartin Burger, Andreas Neubauer
Leukemia & Lymphoma|August 10, 2011
Gastric mucosa-associated lymphoid tissue lymphoma: how to attack the T… for two?Andreas Neubauer, Minh Huynh
Innere Medizin (Heidelberg, Germany)|July 25, 2025
[Cellular therapy options in Internal Medicine]Andreas Neubauer, Michael Hallek
Leukemia & Lymphoma|December 29, 2004
Interferon alpha and T-cell responses in chronic myeloid leukemiaAndreas Burchert, Andreas Neubauer
Immunopharmacology and Immunotoxicology|June 13, 2022
Rituximab induces a flare-up of activated neutrophil extracellular traps under <i>in vitro</i> conditionsJoerg Hoffmann, Samira Roesner, Andreas Neubauer
The New England Journal of Medicine|June 23, 2021
Genome Sequencing in Myeloid CancersElisabeth Mack, Jennifer Kremer, Andreas Neubauer
Hematology (Amsterdam, Netherlands)|May 3, 2023
Abatacept as salvage therapy for life-threatening refractory autoimmune hemolytic anemia: a case reportJoerg Hoffmann, Georg Schliesser, Andreas Neubauer
Leukemia & Lymphoma|June 28, 2011
Poor-risk cytogenetics may be associated with inferior outcome after fludarabine, cytarabine, and amsacrine reduced intensity conditioning in patients with high-risk acute myeloid leukemiaChristian Wilhelm, Andreas Neubauer, Andreas Burchert
Pageof 23

Showing results (1-10 of 224) with videos related to

Sort By:
Pageof 23
Deutsches Arzteblatt International|January 24, 2015
Many questions left openAndreas Neubauer
Innere Medizin (Heidelberg, Germany)|February 22, 2024
[Precision medicine]Andreas Neubauer
Neural Networks : the Official Journal of the International Neural Network Society|February 11, 2003
Analysis of Tikhonov regularization for function approximation by neural networksMartin Burger, Andreas Neubauer
Leukemia & Lymphoma|August 10, 2011
Gastric mucosa-associated lymphoid tissue lymphoma: how to attack the T… for two?Andreas Neubauer, Minh Huynh
Innere Medizin (Heidelberg, Germany)|July 25, 2025
[Cellular therapy options in Internal Medicine]Andreas Neubauer, Michael Hallek
Leukemia & Lymphoma|December 29, 2004
Interferon alpha and T-cell responses in chronic myeloid leukemiaAndreas Burchert, Andreas Neubauer
Immunopharmacology and Immunotoxicology|June 13, 2022
Rituximab induces a flare-up of activated neutrophil extracellular traps under <i>in vitro</i> conditionsJoerg Hoffmann, Samira Roesner, Andreas Neubauer
The New England Journal of Medicine|June 23, 2021
Genome Sequencing in Myeloid CancersElisabeth Mack, Jennifer Kremer, Andreas Neubauer
Hematology (Amsterdam, Netherlands)|May 3, 2023
Abatacept as salvage therapy for life-threatening refractory autoimmune hemolytic anemia: a case reportJoerg Hoffmann, Georg Schliesser, Andreas Neubauer
Leukemia & Lymphoma|June 28, 2011
Poor-risk cytogenetics may be associated with inferior outcome after fludarabine, cytarabine, and amsacrine reduced intensity conditioning in patients with high-risk acute myeloid leukemiaChristian Wilhelm, Andreas Neubauer, Andreas Burchert
Pageof 23